BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute


GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma.

GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end.

It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera.

GigaGen showed Monday in a bioRxiv publication that GIGA-2050 was 100 times more potent than convalescent sera. The company made the comparison using a microneutralization assay that measured the minimum antibody concentrations needed to prevent cytopathic effects induced by live SARS-CoV-2.

Read the full story.